Cargando…

Dermatitis Herpetiformis: An Update on Diagnosis and Management

Dermatitis herpetiformis (DH), presenting with an intense itch and blistering symmetrical rash, typically on the elbows, knees, and buttocks, is a cutaneous manifestation of celiac disease. Though overt gastrointestinal symptoms are rare, three-fourths of patients with DH have villous atrophy in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Reunala, Timo, Hervonen, Kaisa, Salmi, Teea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068693/
https://www.ncbi.nlm.nih.gov/pubmed/33432477
http://dx.doi.org/10.1007/s40257-020-00584-2
_version_ 1783683068081471488
author Reunala, Timo
Hervonen, Kaisa
Salmi, Teea
author_facet Reunala, Timo
Hervonen, Kaisa
Salmi, Teea
author_sort Reunala, Timo
collection PubMed
description Dermatitis herpetiformis (DH), presenting with an intense itch and blistering symmetrical rash, typically on the elbows, knees, and buttocks, is a cutaneous manifestation of celiac disease. Though overt gastrointestinal symptoms are rare, three-fourths of patients with DH have villous atrophy in the small bowel, and the rest have celiac-type inflammatory changes. DH affects mostly adults and slightly more males than females. The mean age at onset is about 50 years. DH diagnosis is confirmed by showing granular immunoglobulin A deposits in the papillary dermis. The DH autoantigen, transglutaminase 3, is deposited at the same site in tightly bound immune complexes. At present, the DH-to-celiac disease prevalence is 1:8. The incidence of DH is decreasing, whereas that of celiac disease is increasing, probably because of improved diagnostics. In DH, the treatment of choice for all patients is a gluten-free diet (GFD) in which uncontaminated oats are allowed. At onset, most patients need additional dapsone to rapidly control the rash and itching. Dapsone can be stopped after a mean of 2 years, and a strict lifelong GFD alone is required. Dietary adherence offers an excellent long-term prognosis for patients with DH, with a normal quality of life and all-cause mortality.
format Online
Article
Text
id pubmed-8068693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80686932021-05-05 Dermatitis Herpetiformis: An Update on Diagnosis and Management Reunala, Timo Hervonen, Kaisa Salmi, Teea Am J Clin Dermatol Review Article Dermatitis herpetiformis (DH), presenting with an intense itch and blistering symmetrical rash, typically on the elbows, knees, and buttocks, is a cutaneous manifestation of celiac disease. Though overt gastrointestinal symptoms are rare, three-fourths of patients with DH have villous atrophy in the small bowel, and the rest have celiac-type inflammatory changes. DH affects mostly adults and slightly more males than females. The mean age at onset is about 50 years. DH diagnosis is confirmed by showing granular immunoglobulin A deposits in the papillary dermis. The DH autoantigen, transglutaminase 3, is deposited at the same site in tightly bound immune complexes. At present, the DH-to-celiac disease prevalence is 1:8. The incidence of DH is decreasing, whereas that of celiac disease is increasing, probably because of improved diagnostics. In DH, the treatment of choice for all patients is a gluten-free diet (GFD) in which uncontaminated oats are allowed. At onset, most patients need additional dapsone to rapidly control the rash and itching. Dapsone can be stopped after a mean of 2 years, and a strict lifelong GFD alone is required. Dietary adherence offers an excellent long-term prognosis for patients with DH, with a normal quality of life and all-cause mortality. Springer International Publishing 2021-01-11 2021 /pmc/articles/PMC8068693/ /pubmed/33432477 http://dx.doi.org/10.1007/s40257-020-00584-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review Article
Reunala, Timo
Hervonen, Kaisa
Salmi, Teea
Dermatitis Herpetiformis: An Update on Diagnosis and Management
title Dermatitis Herpetiformis: An Update on Diagnosis and Management
title_full Dermatitis Herpetiformis: An Update on Diagnosis and Management
title_fullStr Dermatitis Herpetiformis: An Update on Diagnosis and Management
title_full_unstemmed Dermatitis Herpetiformis: An Update on Diagnosis and Management
title_short Dermatitis Herpetiformis: An Update on Diagnosis and Management
title_sort dermatitis herpetiformis: an update on diagnosis and management
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068693/
https://www.ncbi.nlm.nih.gov/pubmed/33432477
http://dx.doi.org/10.1007/s40257-020-00584-2
work_keys_str_mv AT reunalatimo dermatitisherpetiformisanupdateondiagnosisandmanagement
AT hervonenkaisa dermatitisherpetiformisanupdateondiagnosisandmanagement
AT salmiteea dermatitisherpetiformisanupdateondiagnosisandmanagement